Medpage Today on MSN4d
Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer
In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...
Renal & Urology News1d
Local Radiation Therapy for mHSPC Lowers Risk for Prostate Cancer-Related Events
Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).
Renal & Urology News4d
Prostate Cancer Triplet Therapy Including Darolutamide May Be Less Cardiotoxic
A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).
Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide
Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...
Pharmabiz4d
Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer
Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...
Cancer Therapy Advisor8d
CTC Count May Predict PFS, OS in mHSPC
Baseline circulating tumor cell count “may serve as a valuable, noninvasive biomarker” for patients with metastatic hormone-sensitive prostate cancer, according to researchers.
Hosted on MSN22d
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
The sNDA is seeking approval of darolutamide, in combination with androgen deprivation therapy (ADT), in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is an oral ...
Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU
ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion’s collaboration partner Bayer ...
Orion Oyj: Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU
ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion's collaboration ...